Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX-712 in Relapsed/Refractory AML and HR-MDS
NCT05732103Phase 2Recruiting
- Sponsor
- Chordia Therapeutics Inc.
- Start
- Apr 2023
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rogocekib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Chordia Therapeutics Inc.. Started Apr 2023; status: recruiting.
02
Drugs
rogocekib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05732103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05732103.